Skip to content

US · ELAB · BIOTECHNOLOGY

PMGC Holdings Inc. (ELAB) intrinsic value and stock valuation

$1.14as of 2026-11-21 · Mkt cap 1.9M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

PMGC Holdings Inc. DCF and intrinsic value

InvestorsCraft values ELAB with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ELAB’s statements →

PMGC Holdings Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Newport Beach, CA 92660 pmgcholdings.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$590K
20202025
Net income
-$-7.71M
20202025
Free cash flow
-$-6.38M
20202025
Total equity
$7.84M
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20252024202320222021
Revenue$590K$2.47M$1.71M$770K$0.00
Operating income-$-7.38M-$-1.87M-$-1.14M-$-1.79M-$-790K
Net income-$-7.71M-$-6.25M-$-4.3M-$-1.8M-$-780K
EPSd-$-385.5M—-$-143.33M-$-16.36M-$-7.09M
Operating cash flow-$-5.93M-$-5.49M-$-4.56M-$-1.59M-$-660K
Capital expenditure-$-450K-$-10K-$-10K-$-40K-$-30K
Free cash flow-$-6.38M-$-5.49M-$-4.57M-$-1.62M-$-690K
Total assets$12.9M$8.99M$5.19M$1.89M$670K
Total debt$2.64M$0.00$210K$280K$0.00
Net debt-$-2.76M-$-3.98M-$-3.12M-$-870K-$-410K
Total equity$7.84M$6.66M$3.83M$1.13M$450K
Cash and short-term investments$5.4M$3.98M$3.33M$1.15M$410K
Income statement
20252024202320222021
Revenue$590K$2.47M$1.71M$770K$0.00
Cost of revenue$520K$670K$580K$320K$0.00
Gross profit$70K$1.8M$1.13M$450K-$0.00
Research and development expenses$150K$100K$430K$230K$120K
Selling, general and administrative expenses$1.62M$860K$4.03M$1.73M$630K
Other expenses$5.68M$2.7M$970K$280K$30K
Operating expenses$7.45M$3.66M$5.42M$2.24M$780K
Cost and expenses$7.97M$4.33M$6M$2.55M$790K
Interest income$120K$10K$10K$10K$0.00
Interest expense$550K$740K$20K$0.00$0.00
Depreciation and amortization$110K$80K$10K$10K$0.00
Ebitda-$-7.27M-$-3.2M-$-3.66M-$-1.79M-$-780K
Operating income-$-7.38M-$-1.87M-$-1.14M-$-1.79M-$-790K
Total other income/expenses, net-$-370K-$-2.15M-$-520K-$-10K$0.00
Income before tax-$-7.75M-$-4.02M-$-1.66M-$-1.8M-$-780K
Income tax expense$30K$0.00$0.00$0.00$0.00
Net income-$-7.71M-$-6.25M-$-4.3M-$-1.8M-$-780K
Weighted average shares outstanding$20K$0.00$0.00$110K$110K
Weighted average diluted shares outstanding$20K$0.00$30K$110K$110K
Balance sheet
20252024202320222021
Cash and short-term investments$5.4M$3.98M$3.33M$1.15M$410K
Net receivables$340K$10K$40K$10K$0.00
Inventory$100K$0.00$500K$230K$160K
Total current assets$6.87M$6.05M$4.92M$1.55M$640K
Property, plant and equipment, net$2.13M$0.00$0.00$330K$30K
Goodwill and intangible assets$3.87M$2.8M$0.00$0.00$0.00
Long-term investments$0.00$140K$0.00$10K$0.00
Total non-current assets$6M$2.94M$270K$340K$30K
Total assets$12.9M$8.99M$5.19M$1.89M$670K
Accounts payable$700K$480K$600K$210K$100K
Short-term debt$1.59M$0.00$140K$110K$0.00
Deferred revenue$0.00$0.00$40K$10K$0.00
Total current liabilities$3.94M$1.8M$1.3M$590K$220K
Long-term debt$1.06M$0.00$70K$170K$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.09M$530K$70K$170K$0.00
Capital lease obligations$250K$0.00$210K$280K$0.00
Total liabilities$5.03M$2.33M$1.36M$760K$220K
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-21.02M-$-13.27M-$-7.02M-$-2.72M-$-920K
Accumulated other comprehensive income (loss)-$0.00-$0.00$0.00$0.00$0.00
Total equity$7.84M$6.66M$3.83M$1.13M$450K
Total investments$0.00$140K$0.00$10K$0.00
Total debt$2.64M$0.00$210K$280K$0.00
Net debt-$-2.76M-$-3.98M-$-3.12M-$-870K-$-410K
Cash flow statement
20252024202320222021
Net income-$-7.75M-$-6.25M-$-4.3M-$-1.8M-$-780K
Depreciation and amortization$100K$10K$10K$10K$0.00
Stock-based compensation-$-20K$100K$490K$170K$140K
Change in working capital$590K$250K-$-820K$10K-$-20K
Accounts receivable-$-100K-$-10K-$-20K-$-10K-$0.00
Inventory$150K-$-400K-$-270K-$-70K-$-160K
Accounts payable$960K$210K$470K$70K$190K
Net cash provided by operating activities-$-5.93M-$-5.49M-$-4.56M-$-1.59M-$-660K
Investments in property, plant and equipment-$-450K-$-10K-$-10K-$-40K-$-30K
Acquisitions, net-$-2.16M$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-2.77M-$-610K-$-10K-$-30K-$-30K
Common stock issued$6.13M$6.99M$7.46M$2.18M$1.09M
Common stock repurchased-$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$10.1M$6.76M$6.74M$2.36M$1.09M
Net change in cash$1.42M$660K$2.17M$740K$400K
Cash at end of period$5.4M$3.98M$3.33M$1.15M$410K
Operating cash flow-$-5.93M-$-5.49M-$-4.56M-$-1.59M-$-660K
Capital expenditure-$-450K-$-10K-$-10K-$-40K-$-30K
Free cash flow-$-6.38M-$-5.49M-$-4.57M-$-1.62M-$-690K
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About PMGC Holdings Inc.

        PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists. Beyond its core operations, the company also engages in medical scientific research and development and manages various investment firms. Formerly known as Elevai Labs, Inc., the organization adopted its current name, PMGC Holdings Inc., in December 2024. Established in 2020, PMGC Holdings Inc. maintains its headquarters in Newport Beach, California.

        CEO
        Graydon Bensler
        Employees
        34
        Beta
        -0.24

        Explore

        Frequently asked questions

        What is the intrinsic value of PMGC Holdings Inc. (ELAB)?

        InvestorsCraft does not currently publish an intrinsic value for ELAB. How the IC value is calculated.

        Is ELAB undervalued?

        InvestorsCraft does not publish an undervaluation signal for ELAB at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.